Maclear Project PrimeLab
- Written by
- Just P2P
- •
- Updated June 2, 2025
Score B+
PrimeLab d.o.o. is a Slovenian cannabinoid processing company that focuses on extraction, purification, and refinement of hemp-derived raw materials into CBD derivatives for B2B clients in Europe, positioning itself as a key supplier in the European CBD value chain with FDA-approved quality control processes.
PrimeLab seeks to acquire new production equipment aimed at expanding its processing capacity to meet the growth in European demand. Notably by implementing extraction and refinement technologies enabling faster processing, waste reduction, and lower defect rates.
Investment terms
Loan requested : 525,000€
Period : 14 months
Interest rate : 14.8%
Loan requested : Not specified
The 525,000€ loan is part of a targeted expansion strategy in the specialized cannabinoid processing sector. This investment aims to strengthen PrimeLab’s competitive position in the expanding European CBD market. The 14-month term corresponds to industrial equipment acquisition and installation timelines, while the 14.8% interest rate reflects the company’s growth profile.
Risk metrics
Debt/Equity Ratio : 1.45 (Medium risk)
LTV (Loan to Value) : 64% (Low-Medium risk)
Credit History Score : 8/10 (Good creditworthiness)
The risk profile shows balanced leverage with the debt-to-equity ratio of 1.45 falling within acceptable medium-risk parameters for a growing manufacturing company. The 64% LTV provides adequate collateral coverage through a mix of existing fixed assets (360,000€) and dynamic inventory (300,000€ monthly average).
While the company is relatively recent (2022), its credit score of 8/10 demonstrates good creditworthiness. Therefore, its metrics indicate manageable financial risk for a specialized manufacturer in an emerging sector, particularly given secured client contracts and established B2B relationships that provide revenue stability.
Business profile
Geographic Location : Slovenia (EU member states)
Industry Sector : Cannabinoid processing/CBD derivatives
Collateral Type : Company fixed assets + Inventory
The Slovenian location offers a competitive advantage with reduced operational costs while benefiting from access to the European market and optimal logistics infrastructure for continental distribution. The company operates in a high-potential sector where growing demand for pharmaceutical, cosmetic, and nutraceutical applications drives the growth of the European CBD market.
The collateral relies on diversified tangible assets combining production infrastructure and raw material inventory. Following production difficulties in 2023 related to the loss of a senior chemist, PrimeLab restructured its operations in collaboration with the Institute of Chemistry in Belgrade, demonstrating its adaptation and crisis resolution capabilities.
Positive / Risk factors
Positive factors
- 98% of revenues generated through B2B exports to Europe
- 648K€ of confirmed contracts for the first half of 2025
- Focus on high-purity CBD derivatives
- Production challenges overcome (institutional collaboration)
- Expansion targets in France and Italy (high growth)
- Optimal location for distribution in Europe
- FDA-approved internal analytical laboratory
- Compliance systems for premium positioning
Risk factors
- Exposure to evolving CBD regulations in Europe
- Operational history of only 3 years
- Dependence on biomass suppliers
- Concentration on the European CBD market
- Dependence on rare technical skills
- Beyond hemp derivatives, limited diversification
- Growing competition in CBD processing
Score B+
The B+ rating is justified by PrimeLab’s solid positioning in the growing CBD market, its balanced risk metrics (D/E 1.45, LTV 64%, credit 8/10), its 98% export revenues and the 648K€ of secured 2025 contracts, which offset the risks of regulatory uncertainty and recent history.
Although the company is young with recent challenges overcome, its strategic location in Slovenia, the successful resolution of production problems through institutional collaboration, and the planned expansion in France/Italy offer attractive returns for medium risk tolerance investors.
